HRP20110244T1 - Postupak liječenja raka - Google Patents

Postupak liječenja raka Download PDF

Info

Publication number
HRP20110244T1
HRP20110244T1 HR20110244T HRP20110244T HRP20110244T1 HR P20110244 T1 HRP20110244 T1 HR P20110244T1 HR 20110244 T HR20110244 T HR 20110244T HR P20110244 T HRP20110244 T HR P20110244T HR P20110244 T1 HRP20110244 T1 HR P20110244T1
Authority
HR
Croatia
Prior art keywords
cancer
compound
sensitive
use according
susceptible
Prior art date
Application number
HR20110244T
Other languages
English (en)
Inventor
Nirmalini Pandite Arundathy
F. Whitehead Bonnie
T.C. Ho Peter
Benjamin Suttle Albert
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HRP20110244T1 publication Critical patent/HRP20110244T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Spoj formule (I): ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju osjetljivog raka, gdje se navedeni osjetljivi rak bira iz skupine koju čine rak jajnika i rak vrata maternice. Patent sadrži još 10 patentnih zahtjeva.

Claims (11)

1. Spoj formule (I): [image] ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju osjetljivog raka, gdje se navedeni osjetljivi rak bira iz skupine koju čine rak jajnika i rak vrata maternice.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj je spoj formule (I') [image]
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj je spoj formule (I'') [image]
4. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što osjetljivi rak je rak jajnika.
5. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što osjetljivi rak je rak vrata maternice.
6. Upotreba spoja kao što je definiran u patentnim zahtjevima 1-3 u proizvodnji medikamenta za liječenje osjetljivog raka, naznačena time što navedeni osjetljivi rak se bira iz skupine koju čine rak jajnika i rak vrata maternice.
7. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što osjetljivi rak je rak vrata maternice.
8. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što osjetljivi rak je rak jajnika.
9. Farmaceutski pripravak koji sadrži spoj kao što je definiran u patentnim zahtjevima 1-3, uz farmaceutski prihvatljivu podlogu, namijenjen upotrebi u liječenju raka osjetljivog na navedeni spoj, naznačen time što navedeni osjetljivi rak se bira iz skupine koju čine rak jajnika i rak vrata maternice.
10. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što osjetljivi rak je rak jajnika.
11. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što osjetljivi rak je rak vrata maternice.
HR20110244T 2005-11-29 2011-04-04 Postupak liječenja raka HRP20110244T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74030805P 2005-11-29 2005-11-29
PCT/US2006/045777 WO2007064753A2 (en) 2005-11-29 2006-11-29 Cancer treatment method

Publications (1)

Publication Number Publication Date
HRP20110244T1 true HRP20110244T1 (hr) 2011-04-30

Family

ID=37847172

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110244T HRP20110244T1 (hr) 2005-11-29 2011-04-04 Postupak liječenja raka

Country Status (12)

Country Link
US (1) US20090005406A1 (hr)
EP (2) EP2380572A1 (hr)
JP (1) JP2009517397A (hr)
AT (1) ATE500831T1 (hr)
CY (1) CY1111390T1 (hr)
DE (1) DE602006020611D1 (hr)
DK (1) DK1954281T3 (hr)
ES (1) ES2359517T3 (hr)
HR (1) HRP20110244T1 (hr)
PL (1) PL1954281T3 (hr)
SI (1) SI1954281T1 (hr)
WO (1) WO2007064753A2 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058307A1 (en) 2007-11-12 2009-05-13 Cellzome Ag Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
EP2490536A4 (en) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd COMPOSITION AND METHOD
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
ES2547145T3 (es) 2010-10-27 2015-10-02 Novartis Ag Regímenes de dosificación para el tratamiento de enfermedad vascular ocular
EP2773204A4 (en) 2011-10-31 2015-05-27 Glaxosmithkline Intellectual Property Ltd Pazopanib FORMULATION
WO2013123413A2 (en) * 2012-02-17 2013-08-22 Pharmacyclics, Inc. Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
WO2015068175A2 (en) 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
WO2002056912A2 (en) 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US20060252943A1 (en) 2002-06-17 2006-11-09 Amogh Boloor Chemical process
EP1755394A4 (en) * 2004-04-16 2009-08-05 Smithkline Beecham Corp METHOD OF TREATING CANCER

Also Published As

Publication number Publication date
US20090005406A1 (en) 2009-01-01
EP2380572A1 (en) 2011-10-26
ES2359517T3 (es) 2011-05-24
WO2007064753A3 (en) 2007-11-29
EP1954281B1 (en) 2011-03-09
DE602006020611D1 (de) 2011-04-21
DK1954281T3 (da) 2011-05-16
EP1954281A2 (en) 2008-08-13
SI1954281T1 (sl) 2011-06-30
ATE500831T1 (de) 2011-03-15
PL1954281T3 (pl) 2011-07-29
CY1111390T1 (el) 2015-08-05
WO2007064753A2 (en) 2007-06-07
JP2009517397A (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
HRP20110244T1 (hr) Postupak liječenja raka
JP6827092B2 (ja) ルリコナゾール含有外用医薬組成物
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
DE60228857D1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
HRP20090593T1 (hr) Derivati benzimidazola i njihova uporaba kao antagonista aii receptora
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
RS107504A (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
BR0003365A (pt) Composições farmacêuticas
BR0116605A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
HRP20170025T1 (hr) Derivati tetrahidropirolotiazina kao inhibitori bace
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
BRPI0407097A (pt) Antagonista do casr
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
HRP20191869T1 (hr) Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora